STOCK TITAN
  1. Home
  2. PRNB

Principia Biopharma (PRNB) Stock Price, News & Analysis

PRNB NASDAQ

Company Description

Principia Biopharma (NASDAQ: PRNB) is classified in the pharmaceuticals: major industry within the Health Technology sector.

This page collects what Stock Titan holds for PRNB, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib

clinical trial
+0.06%

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

clinical trial
+2.03%

Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis

clinical trial
+3.84%

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

clinical trial
+1.17%

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

clinical trial
-4.05%

Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies

Principia Biopharma has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, conferences, earnings. View all PRNB news →

SEC Filings

View All

No SEC filings available for PRNB.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

PRNB Company Profile & Sector Positioning

Principia Biopharma (PRNB) operates in the Pharmaceuticals: Major industry within the broader Health Technology sector and is listed on the NASDAQ.